Does Rallies show 13F holders for AMLX?

Yes. Rallies tracks hedge fund and 13F ownership data for AMLX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is AMLX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AMLX. It does not provide personalized investment advice.

AMLX (Amylyx Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) is a publicly traded Healthcare sector company. As of May 21, 2026, AMLX trades at $13.58 with a market cap of $1.43B and a P/E ratio of -8.66. AMLX moved +6.83% today. Year to date, AMLX is +19.49%; over the trailing twelve months it is +146.56%. Its 52-week range spans $2.60 to $18.61. Analyst consensus is strong buy with an average price target of $24.57. Rallies surfaces AMLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns AMLX stock?

Hedge funds tracked by Rallies that own AMLX include Viking Global, Orbimed Advisors, and Panagora Asset. The latest tracked quarter is Dec 31, 2023. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Amylyx Pharmaceuticals, Inc. Common Stock.

AMLX Key Metrics

Key financial metrics for AMLX
Metric	Value
Price	$13.58
Market Cap	$1.43B
P/E Ratio	-8.66
EPS	$-1.53
Dividend Yield	0.42%
52-Week High	$18.61
52-Week Low	$2.60
Volume	333
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-144.74M
Gross Margin	0.00%

Top Hedge Funds Holding AMLX

Viking Global holds 2.96M shares of AMLX, changed +0.00% as of Dec 31, 2023.
Orbimed Advisors holds 750.60K shares of AMLX, changed +139.66% as of Sep 30, 2025.
Panagora Asset holds 188.47K shares of AMLX, changed +0.00% as of Sep 30, 2024.

Latest AMLX News

Amylyx Reports $317M Cash, Eyes Q3 Phase 3 Data for Avexitide PBH Trial — Mar 3, 2026

Recent AMLX Insider Trades

Klee Justin B. sold 29.28K (~$423.76K) on Mar 2, 2026.
Cohen Joshua B sold 29.28K (~$424.12K) on Mar 2, 2026.
Bedrosian Camille L sold 6.46K (~$94.21K) on Mar 2, 2026.

AMLX Analyst Consensus

8 analysts cover AMLX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.57.

Common questions about AMLX

Who owns AMLX stock?: Hedge funds tracked by Rallies that own AMLX include Viking Global, Orbimed Advisors, and Panagora Asset. The latest tracked quarter is Dec 31, 2023. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Amylyx Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for AMLX?: Yes. Rallies tracks hedge fund and 13F ownership data for AMLX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AMLX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AMLX. It does not provide personalized investment advice.